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Abstract
Arterial stiffness, blood pressure (BP) and blood lipids may be improved by milk in adults and the effects may be mediated via proteins. However, limited is
known about the effects of milk proteins on central aortic BP and no studies have examined the effects in children. Therefore, the present trial examined the
effect of milk and milk proteins on brachial and central aortic BP, blood lipids, inﬂammation and arterial stiffness in overweight adolescents. A randomised
controlled trial was conducted in 193 overweight adolescents aged 12–15 years. They were randomly assigned to drink 1 litre of water, skimmed milk, whey
or casein for 12 weeks. The milk-based test drinks contained 35 g protein/l. The effects were compared with the water group and a pretest control group
consisting of thirty-two of the adolescents followed 12 weeks before the start of the intervention. Outcomes were brachial and central aortic BP, pulse wave
velocity and augmentation index, serum C-reactive protein and blood lipids. Brachial and central aortic diastolic BP (DBP) decreased by 2·7% (P= 0·036)
and 2·6 % (P= 0·048), respectively, within the casein group and the changes were signiﬁcantly different from those of the pretest control group (P= 0·040
and P= 0·034, respectively). There was a signiﬁcant increase in central aortic DBP, and in brachial and central systolic BP in the whey group compared with
the water group (P= 0·003, P= 0·009 and P= 0·002, respectively). There were no changes in measures of arterial stiffness or blood lipid concentrations. A
high intake of casein improves DBP in overweight adolescents. Thus, casein may be beneﬁcial for younger overweight subjects in terms of reducing the long-
term risk of CVD. In contrast, whey protein seems to increase BP compared with drinking water; however, water may be considered an active control group.
Key words: Whey: Casein: Overweight children: Blood pressure
The prevalence of overweight has increased in the past dec-
ades among children in the Western world(1,2). Overweight
children have higher blood pressure (BP) and abnormal
blood lipid levels compared with normal-weight children(3,4),
and the risk factors track from childhood into adulthood(5).
Post mortem studies have found atherosclerotic lesions in chil-
dren and the extent of the lesions has been related to the num-
ber of cardiovascular risk factors including high BMI, raised
systolic BP (SBP) and diastolic BP (DBP) and abnormal
blood lipid concentrations(6). Also, overweight children have
been shown to have increased arterial stiffness and endothelial
dysfunction compared with normal-weight children(7,8).
Milk is an important source of protein in the Western diet
and epidemiological studies have shown inverse associations
between dairy consumption and metabolic syndrome risk fac-
tors in children and adults(9–11). Also, intervention studies in
overweight or hypertensive adults have shown improvements
in measures of arterial stiffness and brachial BP by milk pro-
teins(12–15), and a meta-analysis of randomised controlled trials
concluded that milk-derived tripeptides have a hypotensive
effect in hypertensive adults(16). Central aortic BP is a better pre-
dictor of cardiovascular events than brachial BP(17) and a recent
study in hypertensive adults showed improvements in central
aortic BP following casein tablets(18). The mechanisms whereby
Abbreviations: ACE, angiotensin-I-converting enzyme; Aix, augmentation index; BP, blood pressure; CRP, C-reactive protein; DBP, diastolic blood pressure; PWV, pulse
wave velocity; SBP, systolic blood pressure.
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milk and milk proteins may affect BP and arterial stiffness have
been linked to the angiotensin-I-converting enzyme (ACE).
Thus, in vitro studies have found ACE-inhibitory peptides in
the amino acid sequences of whey and casein(19).
The blood lipid proﬁle has been improved by longer-term
intake of whey protein in overweight adults(20). The mechan-
ism has been related to the leucine content, which in an animal
study has been found to decrease hepatic cholesterol synthesis
and thereby decrease total plasma cholesterol and LDL-
cholesterol(21). Also in vitro, milk proteins have been shown
to down-regulate genes involved in intestinal fatty acid and
cholesterol synthesis and transport(22).
Since the early abnormalities preceding atherosclerosis occur
in childhood, we ﬁnd it highly relevant to study the potential
beneﬁcial effects of supplementing with dairy products in
young people. Therefore, in the present study we examined
whether there are beneﬁcial effects on brachial and central
aortic BP, blood lipids, inﬂammation and arterial stiffness in
overweight adolescents with a low habitual milk intake by
increasing the intake of low-fat milk and we examined whether
potential effects are mediated by whey or casein.
Method
Subjects
Overweight and obese adolescents aged 12–15 years with an
age- and sex-adjusted BMI corresponding to adult BMI >
25 kg/m2(23) were recruited from November 2008 to
December 2010 through mailed invitations. Invitations were
sent to all children of birth years 1995, 1996, 1997 and 1998
living in the Copenhagen area using extractions from the
National Danish Civil Registration. The exclusion criteria
were milk and yogurt intake >250 ml/d, smoking, chronic dis-
eases and consumption of antibiotics within the last month
before the start of the intervention(24,25).
Study design and methodology
The study was a randomised parallel intervention study con-
ducted at the Department of Nutrition, Exercise and Sports,
University of Copenhagen. The overall aim of the intervention
was to study the effects of skimmed milk, whey and casein com-
pared with drinking water and compared with a pretest control
group on risk factors of the metabolic syndrome in overweight
adolescents. In order to assess the effect of supplementing
with skimmed milk, whey and casein, the study was designed
to include control groups not consuming extra energy. Thus, a
water group was used as a control but because water may be
an active control(26), the study was also designed to include a
control group consuming no test drink. Therefore, a subgroup
of the children was followed for 12 weeks before starting the
intervention (corresponding to a pretest control groupmeasured
at time –12 weeks) and randomised to drink 1 litre/d for 12
weeks of: water, skimmed milk, whey or casein. All adolescents
were examined before the start of the intervention (week 0) and
after 12 weeks of intervention (week 12). All examinations and
measurements were obtained in the fasting state.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the Scientiﬁc Ethics
Committees of the Capital Region of Denmark (journal no.
H-A-2008-084). Written informed consent was obtained
from all the parents and the trial was registered at
ClinicalTrials.gov (NCT00785499).
Test products
The composition of the test drinks is given in Table 1. All test
drinks were ready to drink. The whey and casein drinks were
based on intact protein (whey protein isolate (Lacprodan
DI-9213) and calcium caseinate (Miprodan 40)). All milk-based
test drinks were produced by ARLA Food Ingredients. The
protein content in all milk-based test drinks was 35 g/l. The
skimmed milk, whey and casein drinks were packaged in iden-
tical 200 ml milk cartons and coded by ARLA Food
Ingredients. At the Department of Nutrition, Exercise and
Sports, the water and milk-based test drinks were recoded
using a letter for each drink by a technical assistant, who was
otherwise not involved in the study. The milk-based test drinks
were provided to the children at the start of the intervention and
half way through the intervention and the children were told to
drink ﬁve cartons during the day. The skimmed milk, whey and
casein groups were blinded for participant and investigator. The
water test drink was bottled water produced by Jørgensen
Engros A/S. The water was packaged in 500 ml plastic bottles,
and all bottles were provided to the participants at the start of
the intervention and the children were told to drink two bottles
Table 1. Average nutritional composition of the test drinks
Nutritional content Water Skimmed milk Casein Whey
Energy (kJ/100 g) – 156 136 137
Fat (g/100 g) – 0·47 0·05 0·04
Lactose (g/100 g) – 4·68 4·44 4·45
Protein (g/100 g) – 3·47 3·46 3·48
Casein:whey ratio 80:20 100:0 0:100
Amino acids (mol%) –
Asp – 7·76 6·83 10·96
Thr – 4·53 4·13 7·75
Ser – 7·11 7·22 6·12
Glu – 19·07 19·55 16·12
Pro – 10·73 12·02 6·6
Gly – 3·19 3·06 2·74
Ala – 4·77 4·26 7·06
Tp Cys – 0·86 0·31 2·68
Val – 6·46 6·80 6·23
Met – 2·27 2·39 1·88
Ile – 4·77 4·71 6·23
Leu – 9·47 9·09 10·24
Tyr – 3·40 3·90 2·00
Phe – 3·57 3·86 2·26
His – 2·26 2·35 1·39
Lys – 7·34 6·91 8·41
Arg – 2·46 2·61 1·35
Na (mg/100 g) 0·8 30·0 140·0 10·0
P (mg/100 g) – 100·0 40·0 60·0
Ca (mg/100 g) 3·1 120·0 60·0 10·0
Mg (mg/100 g) 0·2 10·0 0·0 0·0
K (mg/100 g) 0·1 160·0 90·0 10·0
–, Data were not obtained.
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during the day. The water group was not blinded because the
children clearly could taste whether they drank water or a milk-
based test drink. The children were told to eat ad libitum and
maintain their usual physical activity levels during the study.
Compliance
The adolescents were told to record their consumption of test
drinks in booklets with calendar tick boxes and to count the
number of leftover water bottles or milk cartons. Moreover,
serum urea-N was analysed as a measure of recent protein
intake(27) using the kinetic UV assay on Pentra 400 analysers
(Horiba ABX) with intra- and inter-assay variations of 1·0
and 5·3 %, respectively.
Pubertal development
Tanner stage was assessed at the start of the intervention using
self-administrated questionnaires(28,29).
Anthropometry
Examinations were conducted in the fasting state. Weight was
recorded on a digital scale to 0·1 kg accuracy (Tanita BWB600;
Tanita) in underwear and a cotton T-shirt after the bladder had
been emptied. Height was measured to the nearest 0·01 cm
without shoes using a wall-mounted digital stadiometer in tri-
plicate (235 Heightronic Digital Stadiometer; Quick Medical
and Measurement Concepts).
Measurement of plasma lipids and C-reactive protein
As also described previously(24), serum TAG, serum total choles-
terol, serum HDL-cholesterol and serum LDL-cholesterol were
analysed using the speciﬁc ABX Pentra kits on Pentra 400 analy-
sers (Horiba ABX). The intra-assay and inter-assay variations of
the analysis of serum TAG were 2·6 and 3·2%, of total choles-
terol 0·9 and 1·6 %, of HDL-cholesterol 1·2 and 4·0%, and of
LDL-cholesterol 1·3 and 2·7%, respectively. Serum C-reactive
protein (CRP) concentrations were analysed using the speciﬁc
high-sensitivity Horiba ABX CRP CP Assay on Pentra 400 ana-
lysers with a detection limit of 0·10 mg/l. The intra- and inter-
assay variations were 3·6 and 8·1%, respectively. For serum
CRP, data below the detection limit of 0·10 were set at 0·05
(ten at week –12, forty-four at week 0 and thirty-two at week 12).
Haemodynamics
All haemodynamic measures were obtained after a 10-min rest
in the supine position. Brachial BP was measured three times
using an automatic digital BP device (model UA-787 SN
50802 00005, Kivex; A&D Medical). The average of the last
two measures was used. The CV were 5·4 and 10·7 % for
SBP and DBP, respectively. Pulse wave analysis was used to
derive measures of the augmentation index (Aix), central aortic
SBP and DBP. Radial pulse waves were obtained by placing an
applanation tonometer over the right radial using the
SphygmoCor System (Atcor Medical). This method of
obtaining central aortic pressures has been validated against
invasive methods(30). The CV of central SBP and central
DBP were 1·5 and 0·8 %, respectively. Aix is an index of
the enhancement of the aortic systolic pressure generated by
the return of the reﬂected waves(31). Aix is affected by heart
rate(32) and the values used were those adjusted by the soft-
ware to a standard of 75 beats per min. The coefﬁcient of
repeatability of Aix was 12 %. Pulse wave velocity (PWV)
was recorded at the carotid and femoral sites and calculated
by the software as: PWV =D/Δt (m/s). D was the difference
in distance between the carotid and femoral sites measured
using a measuring tape at the surface distances: (1) the supras-
ternal notch and the femoral pulse; and (2) the suprasternal
notch and the carotid pulse. Δt was the time difference
between the two measuring sites calculated at the foot of the
measured pulse wave in relation to the foot of the electrocar-
diogram (ECG) waveform. The coefﬁcient of repeatability of
PWV was 0·82 m/s and the CV of PWV was 8·5 %.
Statistical analysis
Values presented are means and standard deviations for nor-
mally distributed variables and medians and interquartile ranges
for variables that are not normally distributed. Differences in
characteristics between the four test-drink groups at the start
of the intervention (week 0) were tested by the χ2 test, one-way
ANOVA or the Kruskall–Wallis test. Baseline post hoc pairwise
comparisons were conducted with the signiﬁcance level cor-
rected for multiple testing. Outcome variables were brachial
and central aortic SBP and DBP, PWV and Aix, serum TAG,
serum cholesterol, serum LDL-cholesterol, serum HDL-
cholesterol and serum CRP. Serum cholesterol, LDL-cholesterol,
TAG and CRP were log-transformed before all analyses.
Changes within the 12-week periods were compared by paired
t tests and for serum CRP changes were compared by the
Wilcoxon sign-rank test. Correlations between brachial BP and
central aortic BP were calculated using the Pearson correlation
test. Compliance was calculated as the percentage of planned
intake. Intake estimated from the number of leftovers was
used when the booklet was missing. To assess the effect of
skimmed milk, whey and casein compared with water and com-
pared with the pretest control group, a mixed linear model was
ﬁtted by xtmixed in STATA (StataCorp LP). The model has also
been described elsewhere(25). The following predictors were
included in the model: time (week –12, week 0, week 12), inter-
vention time (week 0, week 12) and the intervention group ×
intervention time interaction. Thus, for all participants a general
time effect (called ‘time’) was assumed corresponding to the
underlying change happening over time with no intervention, i.
e. in the pretest control group. In addition, an intervention
time effect (called ‘intervention time’) was included for each test-
drink group (intervention time × group interaction) during the
intervention period only, corresponding to the additional change
happening over time due to the intervention. For a given inter-
vention group the effect of intervention time corresponded to
the effect compared with the pretest control. The interaction
term was used to assess the effect of each test drink compared
with that in the water group using the latter as the reference
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group in the intervention group variable. We have previously
shown that milk, whey and casein increase age-adjusted
BMI(25). Therefore, for each outcome, a second model was
constructed which also included: BMI, sex, Tanner stage and
age. Sex × test-drink interactions were tested and, if non-
signiﬁcant, the interaction term was removed from the model.
Since the repeated measurement model is based on available
case analysis, data on all subjects measured at the different
time points are shown in the tables. P values below 0·05 were
considered signiﬁcant. All analyses were performed using
STATA 11.0 (StataCorp LP).
Study size and power calculation
The primary outcomes of the study were body composition and
fasting insulin, glucose, blood lipids and CRP whereas the haemo-
dynamic measures were secondary outcomes. Body weight was
used to power the study. A sample size of 200 children with an
expected drop-out of 10 % was selected in order to observe a
difference of 0·4 SD, whichwas assumed to correspond to aweight
difference of 1 kgwith a signiﬁcance level of <0·05 and a power of
80% for each treatment comparison. The power calculation was
performedusing themethodofAltman(33) and themethod implies
that the study is powered to detect a pairwise difference of 0·4 SD in
any of the outcomes, should it exist.
Results
Subjects
A total of 203 adolescents commenced the trial but ten with-
drew before the start of the intervention. Thus, 193 children
(62 % girls) were examined at week 0 (ﬁfty water, forty-seven
casein, forty-eight skimmed milk, forty-eight whey), and, of
those, thirty-two subjects participated in the pretest control
group. A total of twenty children withdrew during the inter-
vention (eleven from the casein group, four from the
skimmed milk group and ﬁve from the whey group); hence
173 adolescents completed the trial (ﬁfty water, thirty-six
casein, forty-four skimmed milk and forty-three whey).
Table 2 shows the characteristics of the subjects at the
start of the intervention. At the start of the intervention,
there were no differences in baseline characteristics or in
any of the primary outcomes between the four test-drink
groups.
Compliance
Mean intake expressed in percentage of planned intake was 95,
92, 91 and 87 % for water, skimmed milk, casein and whey,
respectively. Data with changes in serum urea-N concen-
trations have been published elsewhere(25). Brieﬂy, serum
urea-N increased in the casein and skimmed milk groups com-
pared with the pretest control and serum urea-N increased in
all milk-based test-drink groups compared with the water
group.
Blood lipids
It was not possible to obtain blood samples in two adolescents
from the water and skimmed milk groups, respectively, at week
12. There were no signiﬁcant changes in blood lipids in any of
the test-drink groups over the intervention (Table 3).
Table 2. Characteristics of the test-drink groups at week 0* and the pretest control group at week –12
(Mean values and standard deviations, medians and interquartile ranges (IQR) or number of subjects)
Pretest control (n 32) Water (n 50) Casein (n 47) Skimmed milk (n 48) Whey (n 48)
Mean SD Mean SD Mean SD Mean SD Mean SD
Sex (n)
Male 12 18 18 17 20
Female 20 32 29 31 28
Age (years)
Median 13·7 13·0 13·0 13·1 12·9
IQR 13·2–14·1 12·8–13·5 12·8–13·6 12·5–13·8 12·6–13·4
Tanner stage (n)
1 0 3 2 2 0
2 2 7 10 9 12
3 9 20 22 17 16
4 13 16 8 18 17
5 8 4 5 2 3
Weight (kg) 69·8 7·8 66·9 8·5 66·0 9·0 66·0 10·1 66·2 10·7
Height (cm) 165·5 8·3 162·9 7·6 162·3 7·7 162·4 7·5 162·8 8·7
BMI (kg/m2)
Median 25·1 25·2 24·4 24·7 24·7
IQR 24·3–26·1 23·1–27·0 23·5–26·5 23·5–25·9 23·1–26·2
Brachial SBP (mmHg) 111·4 8·6 111·8 7·9 109·3 7·6 109·1 6·5 111·3 7·4
Brachial DBP (mmHg) 64·3 5·9 65·3 7·6 66·1 5·9 65·3 6·1 64·5 5·7
Central SBP (mmHg)† 94·2 5·8 94·8 5·3 93·6 6·0 93·6 5·7 94·5 5·4
Central DBP (mmHg)† 65·8 5·6 66·5 7·3 67·7 5·8 66·6 6·5 66·2 5·5
SBP, systolic blood pressure; DBP, diastolic blood pressure.
* There were no differences between the four test-drink groups at baseline (week 0).
† Two missing in the pretest control, water and skimmed milk groups, respectively. Three missing in the casein and whey groups, respectively.
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Table 3. BMI and concentrations of blood lipids in the pretest control group and in those drinking water, casein, skimmed milk or the whey drink*
(Medians and interquartile ranges (IQR) or mean values and standard deviations)
Week –12 Week 0 Week 12 Change†
Median IQR Median IQR Median IQR Median IQR Paired test‡ Treatment§ Treatment‖
BMI (kg/m2)¶
Pretest control 25·1 24·3–26·1 25·3 24·6–26·6 – – 0·3 –0·05 to 0·58 P = 0·042 – –
Water – – 25·2 23·1–27·0 25·4 23·7–26·9 0·4 –0·24 to 0·75 P = 0·010 P = 0·321 –
Casein – – 24·4 23·5–26·5 25·6 24·2–26·9 0·8 0·39 to 1·24 P < 0·001 P < 0·001 P = 0·002
Skimmed milk – – 24·7 23·5–25·9 25·3 24·2–27·0 0·6 0·19 to 1·04 P < 0·001 P = 0·001 P = 0·022
Whey – – 24·7 23·1–26·2 25·5 23·8–26·7 0·7 0·28 to 1·20 P < 0·001 P < 0·001 P = 0·009
Cholesterol (mmol/l)**
Pretest control 3·80 3·32–4·29 3·84 3·38–4·56 – – 0·05 –0·09 to 0·32 P = 0·938 – –
Water – – 4·02 3·53–4·66 4·12 3·50–4·45 0·00 –0·31 to 0·32 P = 0·757 P = 0·370 –
Casein – – 3·85 3·61–4·77 4·44 3·79–4·71 0·13 –0·33 to 0·43 P = 0·187 P = 0·509 P = 0·091
Skimmed milk – – 4·34 3·82–4·74 4·26 3·84–4·73 –0·05 –0·26 to 0·27 P = 0·775 P = 0·531 P = 0·782
Whey – – 4·04 3·60–4·93 4·09 3·65–4·63 0·03 –0·30 to 0·27 P = 0·811 P = 0·547 P = 0·757
LDL-cholesterol (mmol/l)**
Pretest control 2·29 1·85–2·76 2·15 1·88–2·79 – – –0·02 –0·12 to 0·12 P = 0·601 – –
Water – – 2·35 1·89–2·90 2·41 1·97–2·89 0·08 –0·27 to 0·26 P = 0·946 P = 0·940 –
Casein – – 2·38 1·98–2·72 2·68 2·13–3·10 0·06 –0·13 to 0·35 P = 0·051 P = 0·087 P = 0·053
Skimmed milk – – 2·53 1·96–3·02 2·58 2·02–2·88 0·04 –0·16 to 0·24 P = 0·827 P = 0·698 P = 0·609
Whey – – 2·25 1·95–2·76 2·26 2·02–2·71 0·06 –0·24 to 0·23 P = 0·700 P = 0·919 P = 0·847
HDL-cholesterol (mmol/l)**
Pretest control P = 0·707 – –
Mean 1·16 1·17 – 0·01
SD 0·19 0·23 – 0·16
Water P = 0·742 P = 0·379 –
Mean – 1·20 1·20 −0·07
SD – 0·21 0·19 0·15
Casein P = 0·980 P = 0·408 P = 0·998
Mean – 1·16 1·15 0·00
SD – 0·27 0·26 0·13
Skimmed milk P = 0·191 P = 0·118 P = 0·415
Mean – 1·20 1·19 −0·03
SD – 0·30 0·27 0·16
Whey P = 0·720 P = 0·412 P = 0·968
Mean – 1·26 1·26 −0·01
SD – 0·32 0·25 0·20
TAG (mmol/l)**
Pretest control 0·81 0·53–1·19 0·87 0·62–1·03 – – –0·04 –0·22 to 016 P = 0·625 – –
Water – – 0·87 0·65–1·22 0·86 0·65–1·04 –0·01 –0·24 to 0·13 P = 0·363 P = 0·267 –
Casein – – 0·73 0·59–0·96 0·87 0·61–1·15 0·07 –0·20 to 0·32 P = 0·226 P = 0·709 P = 0·107
Skimmed milk – – 0·84 0·65–1·15 0·79 0·63–1·14 0·00 –0·20 to 0·16 P = 0·665 P = 0·617 P = 0·503
Whey – – 0·82 0·69–1·15 0·77 0·64–1·03 0·00 –0·28 to 0·14 P = 0·823 P = 0·559 P = 0·565
–, No measurements were performed.
* There were no differences between the four test-drink groups at baseline (week 0).
† For test drinks, calculated as the change from week 0 to week 12; in the pretest control group, calculated as the change from week –12 to week 0.
‡ Level of significance between week 0 and week 12 for the test-drink groups and between week –12 and week 0 for the pretest control group.
§ Level of significance for difference over the intervention between the test-drink group and the pretest control group.
|| Level of significance for difference over the intervention between the milk-based test drink and water.
¶ For BMI, at week –12 (n 32); at week 0 (water (n 50), casein (n 47), skimmed milk (n 48), whey (n 48)); at week 12 (water (n 50), casein (n 36), skimmed milk (n 44), whey (n 43)).
** For blood lipids, at week –12 (n 32); at week 0 (water (n 50), casein (n 47), skimmed milk (n 48), whey (n 48)); at week 12 (water (n 49), casein (n 36), skimmed milk (n 43), whey (n 43)).
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Haemodynamic parameters
Due to difﬁculties in measuring the children, no measure-
ments of PWV were obtained in one subject at week –12, ele-
ven (two water, two casein, six skimmed milk, one whey) at
week 0 and nineteen (six water, four casein, eight skimmed
milk, one whey) at week 12. For pulse wave analysis, no
measurements were obtained in two subjects at week –12,
ten (two water, three casein, two skimmed milk, three whey)
at week 0 and six (three water, two skimmed milk, one
whey) at week 12. At the start of the intervention, brachial
SBP and DBP were 110 (SD 7) and 65 (SD 6) mmHg, respect-
ively. Central aortic SBP, DBP, PWV and Aix were 94 (SD 6)
mmHg, 67 (SD 6) mmHg, 4·78 (SD 0·72) m/s and –0·77 (SD
9·44) %, respectively. There were good correlations between
brachial and central aortic DBP (r = 0·97; P < 0·001) and
between brachial and central aortic SBP (r 0·84; P < 0·001).
At week 0, twenty subjects had brachial SBP ≥ 120 mmHg,
four subjects had brachial DBP≥ 80 mmHg and one subject
had brachial DBP/SBP ≥ 120/80 mmHg.
Brachial DBP decreased in the casein group from week 0 to
week 12 by 2·7 % (P = 0·036) (Table 4) and it decreased com-
pared with the pretest control (P= 0·040). The effect of casein
on brachial DBP compared with the pretest control remained
signiﬁcant after adjusting for BMI, Tanner stage, sex and age
(P = 0·026). There were no signiﬁcant effects of water,
skimmed milk or whey on brachial DBP.
Central DBP decreased from week 0 to week 12 by 3·2 %
within the water group (P = 0·010) and by 2·6 % within the
casein group (P = 0·048). Also, there was a decrease in central
DBP in the water group (P = 0·006) and the casein group (P =
0·034) compared with the pretest control group. The decreas-
ing effects of water and casein remained signiﬁcant compared
with the pretest control group in the model adjusted for BMI,
Tanner stage, age and sex (P = 0·008 and P= 0·017, respect-
ively). There was an increase in central DBP in the whey
group compared with the water group (P = 0·003) and the
effect persisted in the adjusted model (P = 0·008). Finally,
there were no signiﬁcant changes in central DBP in the
skimmed milk group.
There were no signiﬁcant effects of skimmed milk or casein
on brachial SBP or within the whey group compared with
baseline. However, brachial SBP increased in the whey
group compared with the water group (P= 0·009). Also, in
the adjusted model, the increasing effect of whey on brachial
SBP was signiﬁcant compared with the water group (P =
0·012).
Table 4. Blood pressure in the pretest control group and in those drinking water, casein, skimmed milk or the whey drink*
(Mean values and standard deviations)
Week –12 Week 0 Week 12 Change†
Mean SD Mean SD Mean SD Mean SD Paired test‡ Treatment§ Treatment‖
Brachial SBP (mmHg)¶
Pretest control 111·4 8·6 110·9 8·5 – – –0·5 5·8 P = 0·651 – –
Water – – 111·8 7·9 110·8 6·6 –1·1 6·3 P = 0·242 P = 0·513 –
Casein – – 109·3 7·6 110·0 5·8 –0·4 5·4 P = 0·644 P = 0·729 P = 0·763
Skimmed milk – – 109·1 6·5 109·8 7·4 0·7 6·1 P = 0·458 P = 0·962 P = 0·431
Whey – – 111·3 7·4 113·7 9·7 2·0 7·8 P = 0·105 P = 0·098 P = 0·009
Brachial DBP (mmHg)¶
Pretest control 64·3 5·9 63·7 6·1 – – –0·6 4·3 P = 0·443 – –
Water – – 65·3 7·6 63·8 5·8 –1·5 5·6 P = 0·067 P = 0·056 –
Casein – – 66·1 5·9 63·9 5·7 –1·8 5·0 P = 0·036 P = 0·040 P = 0·767
Skimmed milk – – 65·3 6·1 64·7 5·6 –0·5 5·7 P = 0·558 P = 0·294 P = 0·342
Whey – – 64·5 5·7 65·2 5·6 0·6 5·9 P = 0·498 P = 0·793 P = 0·061
Central SBP (mmHg)**
Pretest control 94·2 5·8 93·7 6·5 – – –0·5 4·9 P = 0·604 – –
Water – – 94·8 5·3 93·8 4·8 –1·0 4·4 P = 0·117 P = 0·291 –
Casein – – 93·6 6·0 93·9 5·4 0·1 5·1 P = 0·935 P = 0·766 P = 0·440
Skimmed milk – – 93·6 5·7 92·8 5·9 –0·7 4·5 P = 0·348 P = 0·274 P = 0·930
Whey – – 94·5 5·4 96·6 7·4 1·7 6·0 P = 0·068 P = 0·085 P = 0·002
Central DBP (mmHg)**
Pretest control 65·8 5·6 65·6 6·6 – – 0·0 4·4 P = 0·966 – –
Water – – 66·5 7·3 64·4 5·5 –2·2 5·5 P = 0·010 P = 0·006 –
Casein – – 67·7 5·8 65·7 6·0 –1·8 5·1 P = 0·048 P = 0·034 P = 0·540
Skimmed milk – – 66·6 6·5 66·2 5·7 –0·3 5·5 P = 0·705 P = 0·267 P = 0·061
Whey – – 66·2 5·5 67·1 5·2 0·9 5·2 P = 0·276 P = 0·875 P = 0·003
SBP, systolic blood pressure; –, no measurements were performed; DBP, diastolic blood pressure.
* There were no differences between the four test-drink groups at baseline (week 0).
† For test drinks, calculated as the change from week 0 to week 12; in the pretest control group, calculated as the change from week –12 to week 0.
‡ Level of significance between week 0 and week 12 for the test-drink groups and between week –12 and week 0 for the pretest control group.
§ Level of significance for difference over the intervention between the test-drink group and the pretest control group.
|| Level of significance for difference over the intervention between the milk-based test drink and water.
¶ For brachial blood pressures, at week –12 (n 32); at week 0 (water (n 50), casein (n 47), skimmed milk (n 48), whey (n 48)); at week 12 (water (n 50), casein (n 36), skimmed milk
(n 44), whey (n 43)).
** For central blood pressures, at week –12 (n 30); at week 0 (water (n 48), casein (n 44), skimmed milk (n 46), whey (n 45)); at week 12 (water (n 47), casein (n 36), skimmed milk
(n 42), whey (n 42)).
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The whey group had a signiﬁcantly increased central SBP
compared with the water group (P= 0·002) and the effect
remained signiﬁcant in the model adjusted for BMI, sex,
Tanner stage and age (P = 0·004). There were no signiﬁcant
differences in central SBP in the water, skimmed milk or
casein groups.
BMI was a positive predictor in all models with BP as an
outcome (P< 0·001). There were no interactions between
sex and test-drink groups for any of the BP measurements.
Vascular function and inflammation
CRP concentrations >10 mg/l were considered to be caused
by acute inﬂammatory diseases(34) and were not used in stat-
istical analysis (ﬁve at week 0 (three water, one casein and
one skimmed milk), nine at week 12 (one water, two casein,
two skimmed milk and four whey)). CRP increased from
week 0 to week 12 within the casein group (P= 0·041)
(Table 5). However, there were no signiﬁcant differences
between any of the groups in CRP, PWV or Aix compared
with the pretest control or compared with the water group.
Discussion
In the present study, we have shown that high intakes of casein
for 12 weeks decrease brachial and central aortic DBP in over-
weight adolescents compared with baseline and compared with
a control group consuming no test drink. Also, the study
shows that whey protein increases brachial SBP, central aortic
SBP and central DBP compared with drinking water.
Otherwise, the study shows no effects on inﬂammation or vas-
cular function of skimmed milk, whey or casein compared
with drinking water or compared with consuming no test
drink in overweight but otherwise healthy adolescents.
Central aortic BP is more strongly related to vascular disease
than brachial pressure(17,35) and brachial SBP tend to overesti-
mate central aortic SBP especially in young subjects because of
pronounced ampliﬁcation as the pulse wave moves towards
Table 5. Measurements of arterial stiffness and the concentration of C-reactive protein (CRP) in the pretest control group and in those drinking water,
casein, skimmed milk or the whey drink*
(Mean values and standard deviations or medians and interquartile ranges (IQR))
Week –12 Week 0 Week 12 Change†
Mean SD Mean SD Mean SD Mean SD Paired test‡ Treatment§ Treatment‖
PWV (m/s)¶
Pretest control 4·65 0·58 4·66 0·65 – – –0·04 0·46 P = 0·611 – –
Water – – 4·81 0·72 4·79 0·59 –0·04 0·51 P = 0·647 P = 0·787 –
Casein – – 4·85 0·68 4·86 0·81 0·06 0·46 P = 0·469 P = 0·746 P = 0·517
Skimmed milk – – 4·83 0·88 4·75 0·64 –0·02 0·73 P = 0·899 P = 0·855 P = 0·932
Whey – – 4·62 0·60 4·68 0·61 0·08 0·49 P = 0·265 P = 0·797 P = 0·544
Aix (%)**
Pretest control 0·27 12·21 –0·92 12·08 – – –0·34 10·09 P = 0·860 – –
Water – – 1·59 9·53 –0·66 10·18 –2·12 9·96 P = 0·152 P = 0·869 –
Casein – – –2·23 8·16 –1·02 9·11 1·60 9·00 P = 0·300 P = 0·323 P = 0·333
Skimmed milk – – –0·53 11·19 –3·02 11·36 –2·00 9·42 P = 0·182 P = 0·673 P = 0·489
Whey – – –2·09 8·26 –1·65 9·47 –0·60 10·57 P = 0·719 P = 0·670 P = 0·753
CRP (mg/l)††
Pretest control P = 0·117 – –
Median 0·28 0·37 – 0·05
IQR 0·05–0·81 0·14–1·15 – –0·15 to 0·50
Water P = 0·714 P = 0·315 –
Median – 0·29 0·31 0·00
IQR – 0·11–0·87 0·11–1·01 −0·12 to 0·25
Casein P = 0·041 P = 0·885 P = 0·360
Median – 0·34 0·36 0·01
IQR – 0·09–1·13 0·11–1·87 0·00 to 0·52
Skimmed milk P = 0·063 P = 0·880 P = 0·190
Median – 0·21 0·51 0·04
IQR – 0·05–0·79 0·22–1·20 –0·19 to 0·53
Whey P = 0·209 P = 0·827 P = 0·383
Median – 0·53 0·44 0·05
IQR – 0·11–1·11 0·16–1·21 –0·11 to 0·31
PWV, pulse wave velocity; –, no measurements were performed; Aix, augmentation index.
* There were no differences between the four test-drink groups at baseline (week 0).
† For test drinks, calculated as the change from week 0 to week 12; in the pretest control group, calculated as the change from week –12 to week 0.
‡ Level of significance between week 0 and week 12 for the test-drink groups and between week –12 and week 0 for the pretest control group.
§ Level of significance for difference over the intervention between the test-drink group and the pretest control group.
|| Level of significance for difference over the intervention between the milk-based test drink and water.
¶ For PWV, at week –12 (n 31); at week 0 (water (n 48), casein (n 45), skimmed milk (n 42), whey (n 47)); at week 12 (water (n 44), casein (n 32), skimmed milk (n 36), whey
(n 42)).
** For Aix, at week –12 (n 30); at week 0 (water (n 48), casein (n 44), skimmed milk (n 46), whey (n 45)); at week 12 (water (n 47), casein (n 36), skimmed milk (n 42), whey (n 42)).
†† For CRP, at week –12 (n 32); at week 0 (water (n 47), casein (n 46), skimmed milk (n 47), whey (n 48)); at week 12 (water (n 48), casein (n 34), skimmed milk (n 41), whey
(n 39)).
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the periphery(35). Therefore, in the present study of adoles-
cents we used radial artery applanation tonometry and pulse
wave analysis to derive the central aortic pressures. We
found that central aortic BP correlated well with brachial
BP; however, central aortic SBP was lower than brachial
SBP, which is consistent with other studies, and which is
most pronounced in young subjects(17,35). In a separate
paper using data of the present study we have shown that
whey and casein increased body weight compared with the
pretest control group and compared with drinking water(25).
Thus, in the present study brachial and central aortic DBP
decreased in our casein group despite an increase in body
weight and the effect was stronger after adjustment for BMI.
The reduction of 2·7 % in brachial DBP within the casein
group is consistent with a recent study in overweight adults
which also showed a 3 % reduction in brachial DBP following
both whey and casein consumption(15). Also, a study in pre-
hypertensive adults showed reductions in both SBP and
DBP following 4 weeks with a casein-derived protein hydroly-
sate supplement(12).
We found reductions of casein in both central aortic DBP
and brachial DBP compared with the pretest control; however,
the ﬁndings were most signiﬁcant for central aortic BP, which
we speculate may be due to smaller variations within the
repeated measures. On the other hand, casein may also have
a more pronounced effect on central aortic BP. This is sup-
ported by studies showing that blood pressure-lowering drugs
can have the same effect on brachial BP but different effects
on central aortic pressures(36). The present results are backed
up by a recent study in hypertensive adults, which showed
that casein hydrolysate tablets containing the milk-derived tri-
peptides Val-Pro-Pro (valine-proline-proline) and Ile-Pro-Pro
(isoleucine-proline-proline) improve central aortic BP(18).
Each component of BP seems to be associated with CVD
risk(37); however, DBP seems to be the strongest predictor of
CVD in young individuals below 50 years(38). Therefore, the
reductions of 1·8 mmHg in DBP following casein consump-
tion seen in the present study may probably be beneﬁcial for
younger subjects in terms of reducing CVD risk later in life.
The mechanism behind the improvements in DBP follow-
ing casein consumption may occur through inhibition of the
ACE system. ACE is a multifunctional enzyme that plays a
key role in the regulation of BP. The enzyme system catalyses
the conversion of angiotensin I to angiotensin II, which is a
potent vasoconstrictor and it degrades bradykinin, which is
a potent vasodilator. In vitro studies have found ACE-
inhibitory peptides in the amino acid sequence of both whey-
derived proteins and casein(19).
We were surprised to see an increased effect of whey on bra-
chial SBP, central DBP and central SBP compared with water
since studies in adults have shown no effects of whey(39) or
reduced BP following whey consumption(13–15). The effects
of whey on BP seen in the present study were only slightly atte-
nuated but remained signiﬁcant after adjustment for BMI,
indicating that the increased body weight may only partly
explain the increased BP. There may be several explanations
for the inconsistency between the studies. First, we only
found signiﬁcantly increased effects of whey on BP when
compared with the water group, which showed reductions in
all BP measurements, though only signiﬁcant for central
DBP. In comparison, other studies did not include a control
group that did not consume a whey product(13) or they used
a glucose control group(15), which may adversely affect CVD
risk factors. Second, the majority of our adolescents were
normotensive, considering BP levels of ≥120/80 mmHg as
pre-hypertensive(40), and it may be that whey only reduces
BP in hypertensive subjects. Thus, the study by Fluegel
et al.(13) divided the study group according to BP levels and
did not ﬁnd an effect of whey on BP in normotensive but
only in the pre- and hypertensive subjects and most of the
studies showing reduced effects were conducted in pre- or
hypertensive subjects(13,14). Finally, an explanation for the dis-
crepancy may be that the effect of whey on BP differs during
the life span and to our knowledge no other studies have been
conducted in adolescents.
In a previous cross-sectional study using the present base-
line data, we found a trend toward an inverse association
between milk intake and arterial stiffness measured by
PWV(24). Therefore, we hypothesised that increasing the intake
of skimmed milk would have a beneﬁcial effect on PWV and
Aix as measures of arterial stiffness. The hypothesis was
supported by studies showing reductions in Aix following
consumption of whey or peptide milk for 12 weeks(15,41).
However, the present study does not add support to the
hypothesis that increasing milk intake improves arterial stiff-
ness. Also, we did not ﬁnd any effects of skimmed milk,
whey or casein on CRP compared with the pretest control
group or compared with drinking water, which is consistent
with a recent study using whey and casein in overweight
adults(15) nor did we ﬁnd any effects on blood lipids.
Strength and limitations
The strength of the study is the double-blinded (on the milk-
based test drinks) randomised design conducted in a large
sample of overweight adolescents. The study was powered
to detect a relatively small difference of 0·4 SD in any outcome
variable should it exist and dietary interventions examining the
effects on PWV, Aix and central BP are rarely reported in the
paediatric literature. Water may not be an appropriate control
since studies have shown improvements in weight loss(26) and
the present data also show that all the BP measures were
reduced within the water group, though only central DBP
was signiﬁcantly reduced. Other studies have used
carbohydrate-rich drinks(15,20,42). However, these may in them-
selves adversely affect the metabolic syndrome risk factors.
Therefore we decided also to use a pretest control group
which strengthens the conclusions of the present study
because the data show no changes in any of the outcomes
within the pretest control group, indicating that this may be
an appropriate control group.
A limitation is that we had difﬁculties in recruiting the over-
weight adolescents with low habitual milk intakes. We aimed
for ﬁfty adolescents in each of the test-drink groups, and, of
those, ﬁfty adolescents should be followed for 3 months before
starting the intervention as the pretest control group. We
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recruited for the pretest control group in the autumn of 2009
using the birth years 1995 and 1996, but only thirty-two ado-
lescents were enrolled and measured at week –12. Due to
the difﬁculties in obtaining enough participants, we only
recruited for the test-drink groups in 2010 and we used the
birth years 1997 and 1998 because the older adolescents had
been invited previously. Therefore, the pretest control group
ended up being approximately 6 months older when starting
the study (week –12) compared with the mean age of the
four test-drink groups. We performed analyses with adjust-
ments for age, Tanner stage and sex for all the intervention out-
come variables, which did not change the results remarkably.
Also, it is a limitation that the pretest control group was only
recruited in the autumn. Thus, seasonal variations in the out-
comes or in lifestyle may potentially have biased the compari-
sons between the test-drink groups and the pretest control
group. However, neither BP nor blood lipids changed within
the 12-week period in the pretest control group. In addition,
the smaller number of subjects in the pretest control group
may have reduced the probability of detecting differences
between this and the other groups due to lower power.
Furthermore, a limitation of the present study focusing on
the effects of milk-based test drinks on haemodynamic vari-
ables is that skimmed milk, whey and casein previously were
found to increase body weight. We hypothesised that increasing
the intake of skimmed milk, whey and casein would reduce
body weight in overweight adolescents with habitual low milk
intakes. Thereby we assumed that the children were able to
regulate their energy intake as seen in other ad libitum studies
with dairy products in children(43–46). We also assumed that
the increased protein intake would increase satiety and hence
decrease energy intake as seen in adults(47–49). The hypothesis
was supported by an adult study showing that a high-protein
diet in ad libitum settings increases weight loss(50). However,
we performed the analyses with adjustments for BMI, which
did not change the results remarkably. Finally, it was not poss-
ible to obtain the same mineral content in the test drinks, which
potentially may have affected the results. Thus, Ca has been
found to enhance vasorelaxation(51) and to improve the
blood lipid proﬁle(52,53). Also Na seems to adversely affect
BP and arterial function whereas K and Mg may have ben-
eﬁcial effects on vascular function and BP(54,55). In our test
drinks, Mg concentrations were slightly different between the
test drinks. K content was highest in skimmed milk whereas
Na content was highest in the casein drink. Thus, it seems unli-
kely that the differences in Na and K concentrations could
explain the different BP effects of the test drinks.
In conclusion, the present study demonstrated that a high
intake of casein improves brachial and central aortic DBP in
overweight adolescents despite casein in our previous study
having been shown to increase body weight. Thus, the redu-
cing effects on DBP seem to be independent of body size,
and since raised DBP in subjects aged 20–50 years is known
to increase the risk of CVD(38), casein may be a beneﬁcial non-
pharmacological component for younger overweight subjects
in terms of reducing the long-term risk of CVD. We also
showed that whey protein increases BP compared with drink-
ing water; however, water may not be an optimal control group
since BP was reduced within this group and therefore more
interventions in children are needed to clarify the effects of
whey protein.
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